Navigation Links
Medication does not reduce risk of recurrent CV events among patients with diabetes
Date:3/30/2014

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions.

Cardiovascular disease remains the dominant cause of death among patients with type 2 diabetes. No drug therapy specifically directed against diabetes nor strategy for tight glucose control has been shown to unequivocally reduce the rate of cardiovascular complications in this population, according to background information in the article. In phase 2 trials, aleglitazar significantly reduced glycated hemoglobin levels (measure of blood glucose over an extended period of time), triglycerides, and low-density lipoprotein cholesterol and increased high-density lipoprotein cholesterol (HDL-C).

A. Michael Lincoff, M.D., of the Cleveland Clinic, and colleagues conducted a phase 3 trial in which 7,226 patients hospitalized for heart attack or unstable angina with type 2 diabetes were randomly assigned to receive aleglitazar or placebo daily. The AleCardio trial was conducted in 720 hospitals in 26 countries throughout North America, Latin America, Europe, and Asia-Pacific regions.

The trial was terminated early (July 2013) after an average follow-up of 104 weeks, due to lack of efficacy and a higher rate of adverse events in the aleglitazar group.

The researchers found that although aleglitazar reduced glycated hemoglobin and improved serum HDL-C and triglyceride levels, the drug did not decrease the time to cardiovascular death, nonfatal heart attack, or nonfatal stroke (primary end points). These events occurred in 344 patients (9.5 percent) in the aleglitazar group and 360 patients (10.0 percent) in the placebo group.

Aleglitazar use was associated with increased risk of kidney abnormalities, bone fractures, gastrointestinal bleeding, and hypoglycemia (low blood sugars).

"These findings do not support the use of aleglitazar in this setting with a goal of reducing cardiovascular risk," the authors conclude.


'/>"/>

Contact: Wyatt DuBois
DUBOISW@ccf.org
216-904-3344
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Erectile dysfunction can be reversed without medication
2. Electronic medication alerts designed with provider in mind reduce prescribing errors
3. One in 5 older Americans take medications that work against each other
4. Anti-psychotic medications offer new hope in the battle against glioblastoma
5. Blood pressure medications given right after stroke not beneficial, study finds
6. MIT robot may accelerate trials for stroke medications
7. Driving Fear Program Review
8. How This Program Helps People Conquer Their Fear Without Any Medication – Vinamy
9. Personal health record associated with improved medication adherence
10. Fresno California's Hear for Life Hearing Aid Centers Publishes Warnings about Medications that Lead to Hearing Loss
11. Audiologists at American Hearing & Balance in Marina del Rey CA Educate Consumers About Everyday Medications That Cause Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. ... for Jardiance (empagliflozin) to reduce the risk of cardiovascular ... and cardiovascular disease. "Cardiovascular disease is ... 2 diabetes mellitus," said Jean-Marc Guettier , M.D., ... Products in FDA,s Center for Drug Evaluation and Research. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder ... Compañía, el INSTI HIV Self Test , a los miembros de la ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology: